---
layout: post
title: "Advisory Committee; Pulmonary-Allergy Drugs Advisory Committee; Renewal"
date: 2026-02-05 18:59:26 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-12370
original_published: 2022-06-08 00:00:00 +0000
significance: 8.00
---

# Advisory Committee; Pulmonary-Allergy Drugs Advisory Committee; Renewal

**Published:** February 05, 2026 18:59 UTC
**Source:** Federal Register
**Original Published:** June 08, 2022 00:00 UTC
**Document Number:** 2022-12370

## Summary

The Food and Drug Administration (FDA) is announcing the renewal of the Pulmonary-Allergy Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Pulmonary- Allergy Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the May 30, 2024, expiration date.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/06/08/2022-12370/advisory-committee-pulmonary-allergy-drugs-advisory-committee-renewal)
- API: https://www.federalregister.gov/api/v1/documents/2022-12370

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
